Vbi Vaccines Inc. Watch

from 8-K 24 pages Iogen Corporation, (Hereinafter Called the “Sub-Sublandlord”), - And - Variation Biotechnologies Inc., (Hereinafter Called the “Sub-Subtenant”)

from 8-K 4 pages Waiver Agreement

from 10-K 17 pages Evaluation and Option Agreement

from 10-K 47 pages Pledge and Security Agreement

from 8-K 5 pages Vbi Vaccines Inc. Board of Directors Services Agreement

from 8-K 29 pages Securities Purchase Agreement

from 8-K/A 36 pages Collaboration and Option License Agreement

from 8-K 7 pages This Agreement Amends and Restates in Its Entirety the Amended Leak-Out Agreement Between US Dated November 14, 2014 (This “Second Amended Leak-Out Agreement”) and Is Being Delivered to You in Connection With That Certain Agreement and Plan of Merger (The “Merger Agreement”), Dated as of May 8, 2014 (The “Execution Date”), by and Among Vbi Vaccines Inc., a Delaware Corporation Whose Common Stock (“Common Stock”) Is Listed on the NASDAQ Capital Market Under the Symbol Vbiv (The “Company”); Variation Biotechnologies (US), Inc., a Delaware Corporation (The “Subsidiary”); and Vbi Acquisition Corp., a Delaware Corporation and a Wholly-Owned Subsidiary of the Company (“Merger Sub”). on July 25, 2014 (The “Merger Date”), the Subsidiary Merged Into the Merger Sub, With the Subsidiary Being the Surviving Company (The “Merger”)

from 10-Q 8 pages This Agreement Amends and Restates in Its Entirety the Leak-Out Agreement Between US Dated September 22, 2014 (This “Amended Leak-Out Agreement”) and Is Being Delivered to You in Connection With That Certain Agreement and Plan of Merger (The “Merger Agreement”), Dated as of May 8, 2014 (The “Execution Date”), by and Among Vbi Vaccines Inc., a Delaware Corporation Whose Common Stock (“Common Stock”) Is Listed on the NASDAQ Capital Market Under the Symbol Vbiv (The “Company”); Variation Biotechnologies (US), Inc., a Delaware Corporation (The “Subsidiary”); and Vbi Acquisition Corp., a Delaware Corporation and a Wholly-Owned Subsidiary of the Company (“Merger Sub”). on July 25, 2014 (The “Merger Date”), the Subsidiary Merged Into the Merger Sub, With the Subsidiary Being the Surviving Company (The “Merger”)

from 8-K 6 pages This Agreement (The “Leak-Out Agreement”) Is Being Delivered to You in Connection With That Certain Agreement and Plan of Merger (The “Merger Agreement”), Dated as of May 8, 2014 (The “Execution Date”), by and Among Vbi Vaccines Inc. (F/K/a Paulson Capital (Delaware) Corp.), a Delaware Corporation (“The Company”); Variation Biotechnologies (US), Inc., a Delaware Corporation (The “Subsidiary”); and Vbi Acquisition Corp., a Delaware Corporation and a Wholly-Owned Subsidiary of the Company (“Merger Sub”). on July 25, 2014 (The “Merger Date”), the Subsidiary Merged Into the Merger Sub, With the Subsidiary the Surviving Company (The “Merger”)

from S-8 11 pages Variation Biotechnologies (US), Inc. 2006 Stock Option Plan

from 8-K 2 pages First Amendment to Paulson Capital (Delaware) Corp. Board of Directors Services Agreement

from 8-K 2 pages First Amendment to Paulson Capital (Delaware) Corp. Board of Directors Services Agreement

from 8-K 2 pages First Amendment to Paulson Capital (Delaware) Corp. Board of Directors Services Agreement

from 8-K 2 pages First Amendment to Paulson Capital (Delaware) Corp. Board of Directors Services Agreement

from 8-K 6 pages Paulson Capital (Delaware) Corp. Board of Directors Services Agreement

from 8-K 6 pages Paulson Capital (Delaware) Corp. Board of Directors Services Agreement

from 8-K 5 pages Paulson Capital (Delaware) Corp. Board of Directors Services Agreement

from 8-K 6 pages Paulson Capital (Delaware) Corp. Board of Directors Services Agreement

from 8-K 6 pages Paulson Capital (Delaware) Corp. Board of Directors Services Agreement